Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amoxicillin, quantity: 1 g - injection, powder for - excipient ingredients: - ibiamox is intended for use where the patient?s condition precludes the administration of the oral form of amoxicillin. it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms.,note: therapy should be guided by bacteriological studies, including sensitivity tests, and clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxicillin sodium may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,septicaemia: (bacterial) h. influenzae; e. coli (see section 5.1 pharmacodynamic properties - microbiology); p. mirabilis; streptococcus; strep. pneumoniae; strep. faecalis and salmonella typhi.,skin and skin structure: staphylococcus (non-penicillinase-producing), streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology).,respiratory, acute and chronic: h. influenzae; streptococcus; strep. pneumoniae; staphylococcus (non-penicillinase producing); e. coli (see section 5.1 pharmacodynamic properties - microbiology).,genitourinary tract (complicated and uncomplicated), acute and chronic: e. coli (see section 5.1 pharmacodynamic properties - microbiology); p. mirabilis and strep. faecalis.,gonorrhoea: n. gonorrhoeae (nonpenicillinase producing),prophylaxis of endocarditis: amoxicillin sodium may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with prosthetic heart valves or those who have previously had endocarditis.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

physicians total care, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - estradiol/norethindrone acetate tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the: - treatment of moderate to severe vasomotor symptoms associated with menopause. - prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. the mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin d intake, and when indicated, pharmacologic therapy. postmenopausal women require an average of 1500 mg/day of elemental calcium. therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. vitamin d supplementation of 400-800 iu/day may also be required to ensure adequate daily intake in postmenopausal women. estradiol/norethindrone acetate tablets 1.0 mg/0.5 mg is also in

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - fosaprepitant dimeglumine, quantity: 245.3 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: dilute hydrochloric acid; polysorbate 80; lactose; disodium edetate; sodium hydroxide - fosaprepitant-aft, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy (see section 4.2 dose and method of administration),? moderately emetogenic cancer chemotherapy (see section 4.2 dose and method of administration).

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - romidepsin, quantity: 10 mg - injection, powder for - excipient ingredients: povidone; dilute hydrochloric acid - istodax is indicated for the treatment of peripheral t-cell lymphoma in patients who have received at least one prior systemic therapy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.12 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: nitrogen - pantoprazole sandoz is indicated for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients who gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole sodium, quantity: 42.56 mg (equivalent: omeprazole, qty 40 mg) - injection, powder for - excipient ingredients: nitrogen; sodium hydroxide; disodium edetate - short-term use when omeprazole cannot be administered orally for, or during, the following conditions. treatment of duodenal ulcer, gastric ulcer and ulcerative oesophagitis. treatment of zollinger-ellison syndrome. long-term prevention of relapse in healed severe reflux oesophagitis (grades 3 and 4), and gastric and duodenal peptic ulceration in patients proven to be helicobacter pylori negative whose ulceration is not associated with ingestion of nsaids, when oral therapy is not possible. omeprazole sandoz iv should be replaced with oral therapy as soon as practicable